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Abstract
Introduction: Affordable and sensitive screening methods for acute hepatitis C (HCV) are necessary to successfully intervene
in the current HCV epidemic among HIV-positive men having sex with men. HCV core antigen (Ag) testing has been proven
effective in diagnosing chronic HCV-infected patients at low costs. We studied the characteristics of HCV Ag testing in acute
HCV-infected HIV-positive patients.
Methods: Plasma samples were selected from acutely HCV genotype 1-infected patients treated with peginterferon, ribavirin
and boceprevir in the Dutch Acute HCV in HIV Study. The control group consisted of HIV-positive patients with a newly raised
alanine aminotransferase (ALT) (>41 U/L) in whom HCV RNA was undetectable and who were tested for HCV Ag. Spearman
correlation coefficient between HCV RNA and HCV Ag was calculated together with the sensitivity and specificity of HCV Ag
testing at acute HCV diagnosis.
Results and discussion: Upon acute HCV diagnosis, HCV Ag was identified in 39 out of 44 patients with detectable HCV RNA
levels. In all 23 control patients without detectable HCV RNA in plasma, HCV Ag was undetectable as well. This resulted in a
sensitivity and specificity of HCV Ag of respectively 89% (95% CI 75–96) and 100% (95% CI 82–100). The correlation between
HCV Ag and HCV RNA was 0.97 (p < 0.001) upon diagnosis.
Conclusion: The data presented in this study suggest that HCV Ag testing is a sensitive and specific method that can be used
in diagnosing AHCV in HIV-infected patients.
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Introduction
There are ongoing epidemics of acute hepatitis C virus (AHCV)
infections among HIV-positive men having sex with men and
injecting drug users throughout the world [1,2]. AHCV infec-
tions are not easily identified because few clinical symptoms
characterize the early stage of HCV infection and antibodies are
often absent during the early phase of infection [3]. Since 2009
reliable and easily performed automated HCV antigen (Ag) tests
are available for the diagnosis of chronic HCV [4]. HCV Ag has
shown to correlate well with HCV RNA in chronic HCV but in
AHCV infections data are currently sparse [5,6]. Because the
use of HCV RNA amplification is a sensitive but expensive
method, there is an unmet need for affordable alternatives.
The objective of this study was to determine the perfor-
mance of the HCV Ag detection as a tool to diagnose AHCV
infections in HIV-infected patients.
Methods
Plasma and serum samples used for this study came from
AHCV genotype 1-infected patients treated in the Dutch
Acute HCV in HIV Study (DAHHS) [7]. All patients signed a
written informed consent and this study was registered
under NCT01912495. The availability of samples during
the very early stage of infection in this study enabled us
to study HCV Ag expression and antibody seroconversion in
this well-defined patient group.
An AHCV-infected patient was defined as a patient in
whom HCV RNA could be detected and in whom chronic
HCV was excluded by testing stored plasma from a preced-
ing outpatient clinic visit for a chronic HIV infection. This
included testing for the presence of HCV RNA or HCV
antibodies. When this was impossible, a patient was con-
sidered to have an AHCV if ALT levels had been normal
previously and a negative HCV antibody test had been
documented somewhere in the past. Within the DAHHS,
screening and baseline (start of treatment) samples were
taken within 26 weeks after the calculated transmission
date (midpoint between last negative and first positive
HCV RNA). For the current study, the first available sample
in which HCV RNA was identified is further referred to as
“diagnosis”.
To measure the specificity of the HCV Ag test we selected
male patients of the Dutch ATHENA cohort with a newly
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raised ALT (>41 U/L) which was observed during regular ALT
screening at least twice per year and who had an undetect-
able HCV RNA at the time of the ALT elevation [8]. These
patients were selected from the HIV outpatient clinic of the
Erasmus MC hospital.
All plasma samples were tested for HCV RNA (Cobas CAP/
CTM V2, Roche Diagnostics, Almere, the Netherlands or
Abbott Realtime M2000, Hoofddorp, the Netherlands), HCV-
core antigen (Architect HCV Ag assay, Abbott, Hoofddorp, the
Netherlands) and HCV IgG antibody testing was done on
serum (Liaison XL anti-HCV, Diasorin, Anderlecht, Belgium).
For the HCV Ag test, all data were analysed using the pre-
defined cutoff ratio as previously defined for chronic HCV by
the manufacturer (>3.00 fmol/L = positive).
The Spearman coefficient (rho, ρ) was calculated
between HCV RNA and HCV Ag. Sensitivity, specificity cal-
culations with 95% confidence intervals based on Wilson
score method with continuity correction were performed of
HCV Ag against HCV RNA as the gold standard test to
diagnose an AHCV infection.
Results and discussion
The presence of HCV Ag at the time of AHCV diagnosis
could be evaluated in 44 out of the 57 patients treated in
the DAHHS. Thirteen patients were excluded because insuf-
ficient plasma was available. All patients were men, median
age was 41 years (interquartile range (IQR) 34–47)) and
median CD4 count 675 cells per mm3 (IQR 443–788).
Median time between last negative and first positive test
was 243 days (IQR 209–320). HIV-positive patients with a
raised ALT and undetectable HCV RNA were used as control
patients (n = 23). All controls were men, median age was
41 years (IQR 33–43) and median CD4 count 560 cells
per mm3 (IQR 390–745).
Upon diagnosis, HCV Ag was observed in 42/44 patients with
detectable HCV RNA (95%) of which 39 patients had levels
above 3.00 fmol/L (89%). Six patients had an HCV RNA load
below 3000 IU/mL. In all of these six patients the Ag loads were
below 3.15 fmol/L, with two of them being undetectable. Both
patients with an undetectable HCV Ag load had very low HCV
RNA loads (221 and 339 IU/mL), low ALT values (31 and 39 U/L),
detectable anti-HCV antibodies and both had high CD4 counts
with an undetectable HIV load.
The correlation coefficient between HCV Ag and HCV
RNA was 0.97 (p < 0.001) at diagnosis. Altogether, the
sensitivity of the HCV Ag test in this study population was
89% in comparison to HCV RNA (95% CI 75–96). One out of
23 HCV RNA-negative samples was positive for HCV Ag but
below the cutoff (0.25 fmol/L) which resulted in a specifi-
city of 100% (95% CI 82–100).
HCV reinfection was diagnosed in 9/44 patients with
detectable HCV RNA, based on phylogenetic analysis or a
change in HCV genotype. After exclusion of these reinfected
patients (in whom antibodies will be present as they remain
antibody positive as a result of the previously cured HCV
infection), 32/35 RNA detectable patients (91%) were HCV
antibody positive at the time of AHCV diagnosis. The three
patients with undetectable HCV antibodies upon diagnosis
all had high HCV Ag loads (>100 fmol/L). At start of AHCV
treatment (<26 weeks after infection) all patients had
seroconverted.
The acute phase of an HCV infection is often marked by
the absence of IgG antibodies while RNA is detected and
the fluctuating viral load during the acute stage [9,10]. This
is represented in our data set because 21% of the patients
had an HCV RNA load between 15 and 10.000 IU/mL.
Remarkably, we found an antibody seroconversion rate of
91% after 121 days of infection. This is in contrast to a
previous large study that found a substantially lower ser-
oconversion rate [10]. This early seroconversion in the total
group of acute HCV-infected patients suggests that antibo-
dies are still of use in diagnosing acute infection.
Unfortunately, the DAHHS included only genotype 1 patients
(98% 1a), which is the genotype that is present in approxi-
mately 60–80% of AHCV-infected HIV-positive patients in
Europe [1,9,11]. We cannot draw definite conclusions on the
use of HCV Ag testing for the detection of other HCV genotypes.
However, in previous studies on the use of HCVAg in chronically
HCV-infected patients, no difference between HCV genotypes
was reported [12,13]. Additionally, based on our results, the
effect of HIV infection on the detection of HCV Ag during the
acute phase cannot be established. Therefore we cannot con-
cludewhether the HCV Ag test will perform similarly in high-risk
HIV-negative patients. A recent meta-analysis on the perfor-
mance of HCV Ag testing between HIV-positive and -negative
patients in chronic HCV-infected patients unfortunately lacked
sufficient power to draw conclusions [14].
If the goal of HCV detection is to reduce transmission or
eliminate the virus, a test with 100% sensitivity would be
ideal. The sensitivity of the HCV Ag test could be improved
when the cutoff ratio of 3.00 fmol/L that was validated for
the use in patients chronically infected with HCV would be
ignored and every patient with a detectable signal would be
confirmed with HCV RNA. This would result in an increased
sensitivity of the HCV Ag test of 95% but also a small
decrease of specificity to 96% and thus a small increase in
unnecessary HCV RNA testing to confirm the positive HCV
Ag test. Thus, in a context where avoiding a delay in the
diagnosis of an acute HCV infection would be crucial, the
use of any level of HCV Ag detection as the cutoff for HCV
RNA confirmatory testing may be preferable. Also in case of
a patient with high-risk factors, a raised ALT and a comple-
tely undetectable HCV Ag signal, a treating physician should
consider HCV RNA testing to prevent a missed AHCV infec-
tion and thereby ongoing transmission.
Finally, given the much higher cost of HCV RNA testing,
the use of an HCV Ag test (and if positive followed by HCV
RNA testing) is probably more cost-effective to diagnose or
exclude an acute HCV infection in an HIV-positive patient
with a new ALT elevation.
Conclusions
This study suggests that HCV Ag testing is a sensitive and
specific method that can be used for the purpose of diag-
nosing AHCV in HIV-infected patients.
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